{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:09:47Z","timestamp":1789524587309,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jid.2016.02.808","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T03:16:36Z","timestamp":1458270996000},"page":"1373-1381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Impact of the HLA-B58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions"],"prefix":"10.1016","volume":"136","author":[{"given":"Chau Yee","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jr","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Lang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jian Jan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chung","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-Yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2016.02.808_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.alit.2015.01.002","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004\u20132013","volume":"64","author":"Abe","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.jid.2016.02.808_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jid.2016.02.808_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jid.2016.02.808_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1871528111312010004","article-title":"Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules","volume":"12","author":"Calogiuri","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jid.2016.02.808_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jid.2016.02.808_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with\u00a0allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2016.02.808_bib10","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2016.02.808_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.jid.2016.02.808_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5415\/apallergy.2015.5.2.59","article-title":"Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms","volume":"5","author":"Dao","year":"2015","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jid.2016.02.808_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2016.02.808_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.1780310318","article-title":"Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol","volume":"31","author":"Emmerson","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2016.02.808_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Goncalo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jid.2016.02.808_bib17","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2016.02.808_bib18","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jid.2016.02.808_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jid.2016.02.808_bib20","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jid.2016.02.808_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.ajkd.2006.10.007","article-title":"Epidemiological features of CKD in Taiwan","volume":"49","author":"Kuo","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jid.2016.02.808_bib23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jid.2016.02.808_bib24","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?","volume":"49","author":"Lee","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jid.2016.02.808_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2008.02.021","article-title":"Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Lee","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2016.02.808_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1445-5994.2011.02567.x","article-title":"Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?","volume":"42","author":"Lee","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.jid.2016.02.808_bib27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2016.02.808_bib28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jaci.2014.09.041","article-title":"Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction","volume":"135","author":"Lin","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2016.02.808_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jid.2016.02.808_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis and Rheum"},{"key":"10.1016\/j.jid.2016.02.808_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2016.02.808_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/RHU.0b013e31829372e6","article-title":"Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol","volume":"19","author":"Paisansinsup","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jid.2016.02.808_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.jid.2016.02.808_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40264-012-0008-4","article-title":"Stevens-Johnson Syndrome and toxic epidermal necrolysis: improving the support to victims","volume":"36","author":"Roujeau","year":"2013","journal-title":"Drug Safety"},{"key":"10.1016\/j.jid.2016.02.808_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2016.02.808_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10067-010-1461-z","article-title":"Hyperuricemia and metabolic syndrome: associations with chronic kidney disease","volume":"30","author":"See","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jid.2016.02.808_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jid.2016.02.808_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*58:01 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jid.2016.02.808_bib40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2016.02.808_bib41","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2016.02.808_bib42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*58:01 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jid.2016.02.808_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","article-title":"A\u00a0new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders","volume":"132","author":"Wang","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2016.02.808_bib44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.det.2004.08.001","article-title":"Adverse drug interactions and reactions in dermatology: current issues of clinical relevance","volume":"23","author":"Wong","year":"2005","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jid.2016.02.808_bib45","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jid.2016.02.808_bib46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jid.2016.02.808_bib47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16308715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16308715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T23:54:01Z","timestamp":1542930841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X16308715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0022202X16308715"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2016.02.808","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the HLA-B*58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2016.02.808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}